Advanced Enzyme Technologies Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Mukund Kabra
Chief executive officer
₹29.3m
Total compensation
| CEO salary percentage | 22.9% |
| CEO tenure | 24.9yrs |
| CEO ownership | 1.6% |
| Management average tenure | no data |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Aug 20
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Jul 19Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
Jul 13Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
Apr 08Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Sep 23Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Feb 03Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Aug 11With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
May 13Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
Mar 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?
Mar 13Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
Feb 21Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 18I Built A List Of Growing Companies And Advanced Enzyme Technologies (NSE:ADVENZYMES) Made The Cut
Feb 03
What Kind Of Investors Own Most Of Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)?
Jan 19What Do The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Tell Us?
Dec 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 114%, So Why Not Pay It Some Attention?
Dec 13Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?
Nov 28Are Strong Financial Prospects The Force That Is Driving The Momentum In Advanced Enzyme Technologies Limited's NSE:ADVENZYMES) Stock?
Nov 20Here's Why I Think Advanced Enzyme Technologies (NSE:ADVENZYMES) Might Deserve Your Attention Today
Nov 05What You Need To Know About Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Investor Composition
Oct 21Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?
Oct 06Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Stocks Shoot Up 31% But Its P/E Still Looks Reasonable
Sep 26Our Take On The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES)
Sep 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹1b |
| Mar 31 2024 | ₹29m | ₹7m | ₹1b |
| Dec 31 2023 | n/a | n/a | ₹1b |
| Sep 30 2023 | n/a | n/a | ₹1b |
| Jun 30 2023 | n/a | n/a | ₹1b |
| Mar 31 2023 | ₹24m | ₹6m | ₹1b |
| Dec 31 2022 | n/a | n/a | ₹979m |
| Sep 30 2022 | n/a | n/a | ₹960m |
| Jun 30 2022 | n/a | n/a | ₹995m |
| Mar 31 2022 | ₹22m | ₹6m | ₹1b |
| Dec 31 2021 | n/a | n/a | ₹1b |
| Sep 30 2021 | n/a | n/a | ₹1b |
| Jun 30 2021 | n/a | n/a | ₹1b |
| Mar 31 2021 | ₹21m | ₹5m | ₹1b |
| Dec 31 2020 | n/a | n/a | ₹1b |
| Sep 30 2020 | n/a | n/a | ₹1b |
| Jun 30 2020 | n/a | n/a | ₹1b |
| Mar 31 2020 | ₹19m | ₹5m | ₹1b |
| Dec 31 2019 | n/a | n/a | ₹1b |
| Sep 30 2019 | n/a | n/a | ₹1b |
| Jun 30 2019 | n/a | n/a | ₹1b |
| Mar 31 2019 | ₹17m | ₹4m | ₹1b |
| Dec 31 2018 | n/a | n/a | ₹1b |
| Sep 30 2018 | n/a | n/a | ₹1b |
| Jun 30 2018 | n/a | n/a | ₹1b |
| Mar 31 2018 | ₹15m | ₹4m | ₹901m |
Compensation vs Market: Mukund's total compensation ($USD349.13K) is about average for companies of similar size in the Indian market ($USD365.56K).
Compensation vs Earnings: Mukund's compensation has increased by more than 20% in the past year.
CEO
Mukund Kabra (52 yo)
24.9yrs
Tenure
₹29,259,649
Compensation
Mr. Mukund Madhusudan Kabra serves as a Whole Time Director at Advanced Enzyme Technologies Ltd. since April 1, 2009 and also served as its Director since September 4, 1999. Mr. Kabra began at the junior-m...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Whole Time Director | 24.9yrs | ₹29.26m | 1.63% ₹ 827.3m | |
| Independent Director | 2.1yrs | ₹620.00k | no data | |
| Non-Executive Director | 4.8yrs | ₹350.00k | no data | |
| Independent Non-Executive Director | 7.7yrs | ₹1.18m | 0.0045% ₹ 2.3m | |
| Chairman | 31.4yrs | ₹1.13m | 38.68% ₹ 19.6b | |
| Additional Non-Executive Director | 5.6yrs | ₹260.00k | 2.38% ₹ 1.2b | |
| Independent Director | 5.5yrs | ₹1.19m | no data | |
| Independent Director | 4.2yrs | ₹720.00k | no data | |
| Independent Director | 1.1yrs | no data | no data |
5.5yrs
Average Tenure
55yo
Average Age
Experienced Board: ADVENZYMES's board of directors are considered experienced (5.5 years average tenure).